Does Simcyp Simulator allow you to predict pharmacokinetics in patient populations?
Unlike other modelling tools, the Simcyp Simulator has the added benefit of simulating patient variability. This allows you to predict outcomes in relevant patient populations not just a single value in an average individual.
Click here for more information on Simcyp models.
What is the Simcyp Consortium?
The Simcyp Consortium includes pharmaceutical companies and a US regulatory agency. Other regulators and academic institutes enjoy associate membership status. Members have licenses for the Population-Based Simulator, an allocation of free workshop places, regular contact with the Simcyp team and access to Simcyp training. The Consortium meets annually to give feedback on the Simcyp Simulator and to vote on future directions of Simcyp research and development.
Click here for more information on the Simcyp Consortium.
Why should I use the Simcyp Simulator?
By automating in vitro-in vivo extrapolation, the Simcyp Simulator facilitates the screening of large numbers of compounds, saving time and money.
An added benefit of Simcyp simulations is that they predict outcomes in relevant populations, not just a single value in the average individual. This allows you to identify individuals at extreme risk.
The majority of the world’s leading pharmaceutical companies have validated the Simcyp Simulator and are now using the platform as an integral part of their drug development programmes. Several groups from industry, academia and the regulatory bodies have published their results using Simcyp. Details of these can be found in our citations sections.
What support can I receive from Simcyp?
We offer help and advice on a broad spectrum of DMPK issues. This includes advice on optimal design for metabolic drug-drug interaction studies, interpretation of data and prediction of in vivo ADME from in vitro studies.
Does the Simcyp Simulator predict outcomes in children?
Yes - 'Simcyp Paediatric' allows you to predict pharmacokinetics in neonates, infants and children. For more information, please click here.
Who is the Simcyp Simulator available to?
The Simcyp Population-based Simulator is licensed to Simcyp Consortium members. Currently, 70% of the world's top-40 pharma companies (including all of the top ten) are members of the Consortium.
Academic licenses to support research activities are also granted to Centres of Excellence in Europe, USA and Japan.
How is the Simcyp Simulator provided?
The Simcyp Simulator is provided on a license basis. This enables the platform to be installed on clients' desktop computers or on servers throughout the world.
What epidemiological information is included in the databases?
The Simcyp Simulator incorporates the characteristics of specific disease populations and ethnic groups.
Can I compare my data with that of other drugs?
Yes, Simcyp programs contain databases on the in vitro metabolism of many drugs that are currently used clinically. This allows comparison with the pharmacokinetic behaviour of new compounds and the simulation and prediction of likely drug-drug interactions (DDIs).
Can the Simcyp Simulator predict drug-drug interactions?
Yes, the Simcyp Simulator is widely recognised as the industry’s most sophisticated platform for the prediction of drug-drug interactions in clinical populations. Simcyp programs contain databases on the in vitro metabolism of many drugs that are currently used clinically. This enables the user to predict likely drug-drug interactions.
Where can I find more information?
Please do contact us directly if you have any questions regarding Simcyp, Consortium Membership or any of our products and services.
Can the Simcyp Simulator predict pharmacokinetic outcomes in real-world populations?
Yes. Simcyp algorithms incorporate known variability in demographic and biological components in healthy, disease and ethnic populations. The added benefit of these comprehensive databases is that outcomes can be predicted in relevant populations, not just in the average individual.